Redx Pharma Plc

AIM:REDX Stock Report

Market Cap: UK£58.3m

Redx Pharma Future Growth

Future criteria checks 0/6

Redx Pharma's revenue and earnings are forecast to decline at 37.6% and 22.3% per annum respectively while EPS is expected to decline by 14.2% per annum.

Key information

-22.3%

Earnings growth rate

-14.2%

EPS growth rate

Pharmaceuticals earnings growth19.7%
Revenue growth rate-37.6%
Future return on equityn/a
Analyst coverage

Low

Last updated02 Apr 2024

Recent future growth updates

Recent updates

Does Redx Pharma (LON:REDX) Have A Healthy Balance Sheet?

Aug 22
Does Redx Pharma (LON:REDX) Have A Healthy Balance Sheet?

Is Redx Pharma (LON:REDX) Using Too Much Debt?

May 22
Is Redx Pharma (LON:REDX) Using Too Much Debt?

Bullish: Analysts Just Made A Significant Upgrade To Their Redx Pharma Plc (LON:REDX) Forecasts

Jul 09
Bullish: Analysts Just Made A Significant Upgrade To Their Redx Pharma Plc (LON:REDX) Forecasts

Earnings and Revenue Growth Forecasts

AIM:REDX - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2025N/A-49N/A-481
9/30/202413-26N/A-241
9/30/20234-33-35-35N/A
6/30/20238-31-32-32N/A
3/31/202313-29-30-30N/A
12/31/202216-24-19-19N/A
9/30/202219-18-9-8N/A
6/30/202217-18-8-8N/A
3/31/202216-19-8-7N/A
12/31/202113-20-15-14N/A
9/30/202110-22-22-21N/A
6/30/20218-20-15-14N/A
3/31/20217-18-7-7N/A
12/31/20206-14-4-3N/A
9/30/20206-900N/A
6/30/20205-8-2-2N/A
3/31/20204-6-5-5N/A
12/31/20194-5-5-5N/A
9/30/20193-4-5-5N/A
6/30/20192-5-6-6N/A
3/31/2019N/A-7-8-8N/A
12/31/20180-8-13-13N/A
9/30/20180-9-17-17N/A
6/30/201815-1-4-4N/A
3/31/201831899N/A
12/31/20173151111N/A
9/30/20173021414N/A
6/30/201715-9N/A-1N/A
3/31/2017N/A-19N/A-16N/A
12/31/2016N/A-17N/A-14N/A
9/30/2016N/A-16N/A-13N/A
6/30/2016N/A-14N/A-11N/A
3/31/2016N/A-12N/A-9N/A
12/31/2015N/A-10N/A-8N/A
9/30/2015N/A-8N/A-7N/A
6/30/2015N/A-7N/A-6N/A
3/31/2015N/A-5N/A-5N/A
12/31/2014N/A-4N/A-4N/A
9/30/2014N/A-3N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: REDX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: REDX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: REDX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: REDX's revenue is expected to decline over the next 3 years (-37.6% per year).

High Growth Revenue: REDX's revenue is forecast to decline over the next 3 years (-37.6% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if REDX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/01 01:52
End of Day Share Price 2024/05/01 00:00
Earnings2023/09/30
Annual Earnings2023/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Redx Pharma Plc is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian WhiteCantor Fitzgerald Europe
Martin HallHardman & Co.
Michael MitchellPanmure Liberum Historic (Panmure Gordon)